uniQure — Third Quarter 2026 Earnings Summary

uniQure N.V. reported third-quarter 2026 financial results, posting a net loss of $61.2 million and total revenues of $5.2 million. The company received FDA Priority Review for its Biologics License Application for ifezuntirgene inilparvovec (AMT-130) to treat Huntington's disease, with a target action date of May 1, 2027. Clinical data from the AMT-130 program demonstrated a 44% slowing of disease progression on the primary endpoint at 48 months, and the FDA has aligned on the design of a confirmatory study expected to begin patient screening in the U.S. by the end of 2026. As of September 30, 2026, the company held $768.4 million in cash and investment securities, which is projected to fund operations through 2030.